News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 of the General Regulation of the Autorité des Marchés Financiers
July 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS--(BUSINESS WIRE)-- Regulatory News:
Twitter
LinkedIn
Facebook
Email
Print
Europe
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
·
2 min read
·
Tristan Manalac
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
·
2 min read
·
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
February 3, 2025
·
3 min read
·
Tristan Manalac
Layoffs
Biogen Trims Research Workforce, Higher-Dose SMA Drug Accepted for Regulatory Review
January 23, 2025
·
3 min read
·
Tristan Manalac
